Ulcerative Colitis

Adial Pharmaceuticals Completes Azora Merger, Expands Ulcerative Colitis Pipeline

Adial Pharmaceuticals completed its acquisition of Azora Therapeutics on June 11, 2026, and SEC filings show related equity issuance to Azora holders. The filings also show new RSUs and stock options granted to Adial’s CDO.

J&J reports positive Phase 3 Tremfya data in ulcerative colitis

Johnson and Johnson reported positive Phase 3 data for Tremfya in ulcerative colitis, adding to its IBD catalyst set. The plan below frames the data, the approval backdrop, and the next milestones investors should watch.

Abivax Ulcerative Colitis Drug Shows Strong Efficacy, But Cases of Cancer Raise Concerns

Abivax's obefazimod achieved a 40% placebo-adjusted clinical remission rate in a phase 3 ulcerative colitis trial, but several high-dose patients developed cancers, causing a stock collapse. This analysis examines the efficacy-safety trade-off and implications for pharma deal-making.

Abivax Stock Plummets Amid Safety Concerns in Ulcerative Colitis Trial

Abivax's stock experienced a significant decline of over 37% after releasing new trial data for its ulcerative colitis drug, obefazimod. While the drug demonstrated strong efficacy, the emergence of cancer cases in trial participants has cast a shadow over its prospects.

Obefazimod: Abivax Ulcerative Colitis Drug Faces Efficacy vs. Safety Scrutiny

Abivax's obefazimod has demonstrated significant efficacy in ulcerative colitis trials, generating excitement for potential regulatory approval. However, recent reports of cancer cases necessitate a careful evaluation of its safety profile by investors and business development teams.

MRM Health's MH002 Receives FDA Fast Track Designation for Ulcerative Colitis Treatment

MRM Health's lead microbiome therapeutic MH002 granted FDA Fast Track status for mild-to-moderate ulcerative colitis, accelerating development timeline.

FDA Approves Inflammex: Novel Biologic for Ulcerative Colitis

The FDA has granted approval for Inflammex, a groundbreaking biologic designed to treat ulcerative colitis, marking a significant advancement in patient care.

FDA Approves Stelara: New Ulcerative Colitis Treatment from J&J

Stelara, recently approved by the FDA, provides a new treatment option for ulcerative colitis, promising improved outcomes for patients.